Scott Smallwood has been a hedge fund manager for 25 years and currently lives in Bend, Oregon, USA. He is married and has three children, and his greatest passion in life is his family. An active and athletic person, Scott enjoys a wide range of sports, including climbing, hiking, biking, snowboarding, and kite surfing.

In 2014, Scott was diagnosed with a neuroendocrine tumor in his pancreas, which required a highly complex and life-threatening surgery. The procedure was extremely risky due to the involvement of several major veins with the tumor.

Scott’s advice to anyone diagnosed with a neuroendocrine tumor is to seek multiple opinions from various doctors to determine the best treatment plan. He consulted six different physicians before deciding on surgery. At the Stanford Medical Center, a unique surgical approach was proposed: two surgeons performed the operation, with one focusing on the tumor and the other managing the affected veins. This collaborative effort was highly successful.

In the years following his surgery, Scott underwent additional treatments in the United States, including chemotherapy and liver ablation. These treatments initially showed promise but eventually became less effective as the disease progressed.

When his liver became severely affected by metastases and the disease advanced dramatically, Scott was introduced to Josh Mailman, a fellow neuroendocrine tumor patient and international patient advocate. Josh recommended radiotheranostics treatment with Prof. Baum in Germany. After beginning this treatment in 2021, Scott experienced remarkable results. By 2023, almost no metastases could be detected. The treatment was more than successful, with Prof. Baum referring to Scott as a "super responder." For Scott, it felt like a miracle. He was also astonished by the lack of significant side effects from the radiotheranostics treatment, apart from some mild fatigue.

However, Scott acknowledges the profound impact of his initial surgery, particularly the challenges caused by the hormonal changes it caused. He emphasizes the importance of patients being informed by their doctors about the potential for post-surgical depression, which he believes should be treated with appropriate medication.

Today, Scott describes himself as a happy person who values his family and has returned to the activities that were so important to him before his disease. Reflecting on his journey and the many treatment options he has explored, he notes that he would have chosen radiotheranostics immediately after his surgery had he known about its effectiveness. This insight is part of a learning process that he hopes to share with other patients.

Susanne Simon, Head of Communications and Community of the ICPO Foundation, was honored to welcome Scott Smallwood at the ICPO Foundation in Wiesbaden.